Vycor Medical's Financial Results and Business Highlights for Mid-2025

What are the key highlights of Vycor Medical’s financial results for the three and six months ended June 30, 2025?

Key highlights include a 24% and 28% revenue increase for the Vycor Medical division in the three and six months, respectively, significant operating profit growth, new distribution agreements in France and Spain, and the publication of new clinical papers supporting the efficacy of its products.

How did Vycor Medical’s revenue compare between 2025 and 2024?

For the three months ended June 30, 2025, revenue increased by 22% to $496,353 compared to 2024, and for the six months, it increased by 25% to $932,731, with the Vycor Medical division driving most of the growth.

What contributed to the lower gross profit margin in 2025 compared to 2024?

The lower gross margin in 2025 was attributable to validation and shipping costs of new production as well as changes in the geographical sales mix.

What new markets did Vycor Medical enter into during the six months ended June 30, 2025?

Vycor Medical entered into new distribution agreements for France and Spain, marking important steps in its international expansion strategy.

How many clinical papers involving the ViewSite Brain Access System (VBAS) were published by mid-2025?

By mid-2025, a total of 48 peer-reviewed clinical papers involving VBAS had been published, including five in the first six months of the year.

What was the focus of the new clinical study on NovaVision’s NeuroEyeCoach?

The study compared the effectiveness of using NeuroEyeCoach at home versus in a clinic, concluding that both settings provided meaningful improvements for patients with no significant differences in outcomes.

What are the two business units of Vycor Medical, Inc.?

The two business units are Vycor Medical, which produces the ViewSite™ Brain Access System for neurosurgery, and NovaVision®, which offers therapy programs for visual disorders after stroke or brain injury.

How did the NovaVision division perform in terms of revenue and gross margin for the three months ended June 30, 2025?

The NovaVision division generated revenues of $14,565 with a gross margin of 93% for the three months ended June 30, 2025, compared to $19,029 and a 95% gross margin in 2024.